This study, conducted by Isabel Pavão Martins, Professor at the Faculty of Medicine of the  University of Lisbon (FMUL), illustrates  the use of fremanezumab in patients with episodic or chronic migraine and resistant to other drugs. The study was published in the Journal Club section of the Stop Migraine platform.

"Do anti CGRP mAbs maintain efficacy in patients resistant to other drugs?" This is the “important question” that the trial seeks to answer, the primary objective being the change in the number of migraine days per month.

The study reveals that there is a significant impact, as “both patients with episodic and chronic migraine had a good response to this drug after three months, with a significant reduction in the number of migraine days compared to the placebo group”, explains the specialist.

According to Professor Isabel Pavão Martins, another important conclusion is that action is quick, showing that patients notice results in the first week.

In addition, the study points to significant improvements in the quality of life of patients taking fremanezumab, reducing the levels of depression, difficulty in responding to personal and professional daily tasks, and the use of other medications taken in the event of a crisis.

With regard to safety measures, there is a “very low incidence of adverse effects”.

Watch the full presentation here.